academic article

• Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials..  Leukemia & lymphoma.  59:1624-1633. 2018
• MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A children's oncology group study..  Leukemia.  :-. 2016
• Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. 2015
• Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232..  Blood.  :-. 2015
• Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. 2014
• ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  30:751-757. 2012
• Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study..  Blood.  119:1872-1881. 2012
• Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia..  Blood.  120:4197-4204. 2012
• Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia..  Nature genetics.  43:237-241. 2011